Nebivolol therapy improves QTc and QTcd parameters in heart failure patients

Cardiovascular Journal of Africa

Volumn 23, Issue 4, 2012, Pages 191-193

  Aksoy, S M ^a   Cay, S ^b   Cagirci, G ^a   Sen, N ^b  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Yuksek Ihtisas Heart Education and Research Hospital   (Turkey)

Author keywords

Improvement; Nebivolol; QT dynamics

Indexed keywords

NEBIVOLOL;

ADULT; AGED; ARTICLE; CORRECTED QT DISPERSION; CORRECTED QT INTERVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; QT DISPERSION; QT INTERVAL; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE;

ADRENERGIC BETA-ANTAGONISTS; AGED; BENZOPYRANS; ELECTROCARDIOGRAPHY; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; HEART CONDUCTION SYSTEM; HEART FAILURE; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84861321512     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2011-046     Document Type: Article

References (19)

1. The MERIT-HF study group. Effects of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
2. The CIBIS-II investigators and committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13.
3. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. for the Carvedilol Prospective Randomized Cumulative Survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
4. Flather MD, Shibata MC, Coats AJ, van Veldhuisen DJ, Parkhomenko A, Borbola J, et al.; SENIORS investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225. (Pubitemid 40222359)
5. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric-oxide mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Pressure 2004; 13: 18-33.
6. Kuroedov A, Cosentino F, Luscher TF. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004; 22: 155-168. (Pubitemid 39391186)
7. Galetta F, Franzoni F, Magagna A, Femia FR, Pentimone F, Santoro G, Carpi A. Effect of nebivolol on QT dispersion in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother 2005; 59: 15-19. (Pubitemid 40312274)
8. Vrtovec B, Delgado R, Zewail A, Thomas CD, Richartz BM, Radovancevic B. Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation 2003; 107: 1764-1769. (Pubitemid 36418357)
9. Glancy JM, Weston PJ, Bhullar HK, et al. Reproducibility and automatic measurement of QT dispersion. Eur Heart J 1996; 17: 1035-1039. (Pubitemid 26252521)
10. Murray A, McLaughlin NB, Campbell RWF. Measuring QT dispersion: man versus machine. Heart 1997; 77: 539-542. (Pubitemid 27294693)
11. Haigney MC, Zareba W, Gentlesk PJ, Gentlesk PJ, Goldstein RE, Illovsky M, et al., Multicenter Automatic Defibrillator Implantation Trial II investigators. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Implantation Trial (MADIT) II patients. J Am Coll Cardiol 2004; 44: 1481-1487. (Pubitemid 39303953)
12. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994; 343: 327-329. (Pubitemid 24043180)
13. Day CP, McComb JM, Matthews J, Campbell RWF. Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J 1991; 12: 423-427.
14. Singh BN. CIBIS, MERIT-HF and COPERNICUS trial outcomes: do they complete the chapter on beta-adrenergic blockers as antiarrhythmic and antifibrillatory drugs? J Cardiovasc Pharmacol Ther 2001; 6: 107-110. (Pubitemid 32977705)
15. Singh JP, Musialek P, Sleight P, Davey P, Marinho M, Hart G. Effect of atenolol or metoprolol on waking hour dynamics of the QT interval in myocardial infarction. Am J Cardiol 1998; 81: 924-926. (Pubitemid 28204647)
16. Hintze U, Mickley H, Moller M. Effects of beta-blockers on the relation between QT interval and heart rate in survivors of acute myocardial infarction. Ann Noninvas Electrocardiol 1998; 3: 319-326. (Pubitemid 28509269)
17. Bonnar CE, Davie AP, Caruana L, Fenn L, Ogston SA, McMurray JJ, Struthers AD. QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion. Heart 1999; 81: 297-302. (Pubitemid 29116344)
18. Xie RQ, Cui W, Liu F, Yang C, Pei WN, Lu JC. Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol 2008 Nov 28. [Epub ahead of print].
19. Barr CS, Naas AA, Fenwick M, et al. Enalapril reduces QT dispersion in patients with mild congestive heart failure secondary to coronary artery disease. Am J Cardiol 1997; 79: 328-333. (Pubitemid 27093309)